Whitehawk Therapeutics, Inc. (WHWK)

NCM – Цена в реальном времени. Валюта: USD

3.92

+0.12 (3.16%)

При закрытии: May 12, 2026, 4:00 PM EDT

4.29

+0.37 (9.54%)

До открытия: May 13, 2026, 8:48 AM EDT

Whitehawk Therapeutics, Inc. (WHWK)

Получите доступ ко всем премиум-функциям лучшего инструмента для анализа акций

Finranks

Компания

Контакты

Мы в соцсетях

Whitehawk Therapeutics, Inc. (WHWK)

Whitehawk Therapeutics Reports First Quarter 2026 Financial Results and Recent Highlights

Whitehawk Therapeutics Presents Comprehensive Preclinical Data Highlighting its Next-Generation ADC Portfolio at the AACR 2026

Whitehawk Therapeutics to Participate in Jones Trading Post-AACR Fireside Chat Series

Whitehawk Therapeutics Presents Real-World Analysis Confirming MUC16 as a Highly Expressed, Clinically Relevant Target for Gynecologic Cancers at SGO 2026

Whitehawk Therapeutics to Highlight its Next-Generation ADC Portfolio at the American Association for Cancer Research (AACR) Annual Meeting 2026

Whitehawk Therapeutics Reports Fourth Quarter and Full-Year 2025 Financial Results and Recent Highlights

Whitehawk Therapeutics to Participate in Upcoming Investor Conferences

Видео

No Data

Пресс-релизы

Whitehawk Therapeutics Reports First Quarter 2026 Financial Results and Recent Highlights

Whitehawk Therapeutics Presents Comprehensive Preclinical Data Highlighting its Next-Generation ADC Portfolio at the AACR 2026

Whitehawk Therapeutics to Participate in Jones Trading Post-AACR Fireside Chat Series

Whitehawk Therapeutics Presents Real-World Analysis Confirming MUC16 as a Highly Expressed, Clinically Relevant Target for Gynecologic Cancers at SGO 2026

Whitehawk Therapeutics Reports First Quarter 2026 Financial Results and Recent Highlights

Whitehawk Therapeutics Presents Comprehensive Preclinical Data Highlighting its Next-Generation ADC Portfolio at the AACR 2026

Whitehawk Therapeutics to Participate in Jones Trading Post-AACR Fireside Chat Series

Whitehawk Therapeutics Presents Real-World Analysis Confirming MUC16 as a Highly Expressed, Clinically Relevant Target for Gynecologic Cancers at SGO 2026

Whitehawk Therapeutics to Highlight its Next-Generation ADC Portfolio at the American Association for Cancer Research (AACR) Annual Meeting 2026

Whitehawk Therapeutics Reports Fourth Quarter and Full-Year 2025 Financial Results and Recent Highlights

Whitehawk Therapeutics to Participate in Upcoming Investor Conferences

Видео

No Data

Пресс-релизы

Whitehawk Therapeutics Reports First Quarter 2026 Financial Results and Recent Highlights

Whitehawk Therapeutics Presents Comprehensive Preclinical Data Highlighting its Next-Generation ADC Portfolio at the AACR 2026

Whitehawk Therapeutics to Participate in Jones Trading Post-AACR Fireside Chat Series

Whitehawk Therapeutics Presents Real-World Analysis Confirming MUC16 as a Highly Expressed, Clinically Relevant Target for Gynecologic Cancers at SGO 2026

Search stocks

Whitehawk Therapeutics, Inc. (WHWK)

Получите доступ ко всем премиум-функциям лучшего инструмента для анализа акций

Finranks

Компания

Контакты

Мы в соцсетях

Whitehawk Therapeutics, Inc. (WHWK)

Whitehawk Therapeutics Reports First Quarter 2026 Financial Results and Recent Highlights

Whitehawk Therapeutics Presents Comprehensive Preclinical Data Highlighting its Next-Generation ADC Portfolio at the AACR 2026

Whitehawk Therapeutics to Participate in Jones Trading Post-AACR Fireside Chat Series

Whitehawk Therapeutics Presents Real-World Analysis Confirming MUC16 as a Highly Expressed, Clinically Relevant Target for Gynecologic Cancers at SGO 2026

Whitehawk Therapeutics to Highlight its Next-Generation ADC Portfolio at the American Association for Cancer Research (AACR) Annual Meeting 2026

Whitehawk Therapeutics Reports Fourth Quarter and Full-Year 2025 Financial Results and Recent Highlights

Whitehawk Therapeutics to Participate in Upcoming Investor Conferences

Видео

No Data

Пресс-релизы

Whitehawk Therapeutics Reports First Quarter 2026 Financial Results and Recent Highlights

Whitehawk Therapeutics Presents Comprehensive Preclinical Data Highlighting its Next-Generation ADC Portfolio at the AACR 2026

Whitehawk Therapeutics to Participate in Jones Trading Post-AACR Fireside Chat Series

Whitehawk Therapeutics Presents Real-World Analysis Confirming MUC16 as a Highly Expressed, Clinically Relevant Target for Gynecologic Cancers at SGO 2026

Whitehawk Therapeutics Reports First Quarter 2026 Financial Results and Recent Highlights

Whitehawk Therapeutics Presents Comprehensive Preclinical Data Highlighting its Next-Generation ADC Portfolio at the AACR 2026

Whitehawk Therapeutics to Participate in Jones Trading Post-AACR Fireside Chat Series

Whitehawk Therapeutics Presents Real-World Analysis Confirming MUC16 as a Highly Expressed, Clinically Relevant Target for Gynecologic Cancers at SGO 2026

Whitehawk Therapeutics to Highlight its Next-Generation ADC Portfolio at the American Association for Cancer Research (AACR) Annual Meeting 2026

Whitehawk Therapeutics Reports Fourth Quarter and Full-Year 2025 Financial Results and Recent Highlights

Whitehawk Therapeutics to Participate in Upcoming Investor Conferences

Видео

No Data

Пресс-релизы

Whitehawk Therapeutics Reports First Quarter 2026 Financial Results and Recent Highlights

Whitehawk Therapeutics Presents Comprehensive Preclinical Data Highlighting its Next-Generation ADC Portfolio at the AACR 2026

Whitehawk Therapeutics to Participate in Jones Trading Post-AACR Fireside Chat Series

Whitehawk Therapeutics Presents Real-World Analysis Confirming MUC16 as a Highly Expressed, Clinically Relevant Target for Gynecologic Cancers at SGO 2026